Nick Glover
Director/Board Member at MEI PHARMA, INC.
Net worth: - $ as of 2024-04-29
Active connections
| Name | Gender | Age | Linked companies | Collaboration |
|---|---|---|---|---|
| David Urso | M | 60 | 10 years | |
| Mark Frans van Coeverden de Groot | M | - |
Pattern Pharma, Inc.
 Pattern Pharma, Inc. Pharmaceuticals: MajorHealth Technology Pattern Pharma, Inc. engages in the pharmaceutical industry. Its product named P2PAR addresses the immune failure which underlies infectious diseases and cancers. The company is headquartered in Toronto, Canada. | - |
| Charles Baltic | M | 63 | 13 years | |
| Justin File | M | 53 | 1 years | |
| Fred Driscoll | M | 73 | 6 years | |
| Thomas Reynolds | M | 65 | 11 years | |
| David Walsey | M | - | 6 years | |
| Andrew Williams | M | - |
Pattern Pharma, Inc.
Pattern Pharma, Inc. Pharmaceuticals: MajorHealth Technology Pattern Pharma, Inc. engages in the pharmaceutical industry. Its product named P2PAR addresses the immune failure which underlies infectious diseases and cancers. The company is headquartered in Toronto, Canada. | - |
| Caroline Ruiz | F | - | 2 years | |
| Eric Deng | M | - | 3 years | |
| Jason Sausser | M | - | 2 years | |
| Eugene Park | M | - | 3 years | |
| Elizabeth Acosta | M | - |
Pattern Pharma, Inc.
Pattern Pharma, Inc. Pharmaceuticals: MajorHealth Technology Pattern Pharma, Inc. engages in the pharmaceutical industry. Its product named P2PAR addresses the immune failure which underlies infectious diseases and cancers. The company is headquartered in Toronto, Canada. | - |
| Steven Wood | M | 41 | 1 years | |
| Yann Rioux | M | - |
Pattern Pharma, Inc.
Pattern Pharma, Inc. Pharmaceuticals: MajorHealth Technology Pattern Pharma, Inc. engages in the pharmaceutical industry. Its product named P2PAR addresses the immune failure which underlies infectious diseases and cancers. The company is headquartered in Toronto, Canada. | - |
| Taheer Mehboob Datoo | M | 33 | 1 years | |
| Richard Ghalie | M | 66 | 8 years | |
| Anne Frese | F | - | 2 years | |
| Wendy Cuthbert | F | - |
Viventia Biotech, Inc.
 Viventia Biotech, Inc. BiotechnologyHealth Technology Viventia Biotech, Inc. discovers, develops, manufactures, and commercializes monoclonal antibody products. Its products are used to treat head, neck, and bladder cancers. The company was founded by Albert D. Friesen in 1995 and is headquartered in Toronto, Canada | 18 years |
| John H. Abeles | M | 78 |
Pattern Pharma, Inc.
Pattern Pharma, Inc. Pharmaceuticals: MajorHealth Technology Pattern Pharma, Inc. engages in the pharmaceutical industry. Its product named P2PAR addresses the immune failure which underlies infectious diseases and cancers. The company is headquartered in Toronto, Canada. | - |
| Hans S. Keirstead | M | 57 |
Pattern Pharma, Inc.
Pattern Pharma, Inc. Pharmaceuticals: MajorHealth Technology Pattern Pharma, Inc. engages in the pharmaceutical industry. Its product named P2PAR addresses the immune failure which underlies infectious diseases and cancers. The company is headquartered in Toronto, Canada. | - |
| James Flynn | M | 43 | 1 years |
Connections Chart
Multi-company connection
Former connections
| Name | Gender | Age | Linked companies | Collaboration |
|---|---|---|---|---|
| James Smith | M | 54 |
YM BioSciences, Inc.
 YM BioSciences, Inc. Pharmaceuticals: MajorHealth Technology YM BioSciences, Inc. operates as a drug development company, which manufactures advancing hematology and cancer-related products. It is currently advancing in late-stage products, which include CYT387, an oral small molecule inhibitor of the kinase enzymes JAK1 and JAK2; and Nimotuzumab, an EGFR targeting humanized monoclonal antibody. The company was founded in 1994 and is headquartered in Mississauga, Canada. | 11 years |
| Brian Drazba | M | 63 | 6 years | |
| Thomas M. Zech | M | 72 | 7 years | |
| Daniel Gold | M | 70 | 13 years | |
| Mark Kowalski | M | 69 |
YM BioSciences, Inc.
YM BioSciences, Inc. Pharmaceuticals: MajorHealth Technology YM BioSciences, Inc. operates as a drug development company, which manufactures advancing hematology and cancer-related products. It is currently advancing in late-stage products, which include CYT387, an oral small molecule inhibitor of the kinase enzymes JAK1 and JAK2; and Nimotuzumab, an EGFR targeting humanized monoclonal antibody. The company was founded in 1994 and is headquartered in Mississauga, Canada. | 5 years |
| Christine Anna White | M | 72 | 13 years | |
| Robert E. Pelzer | M | 70 | 7 years | |
| Gregg Smith | M | - |
YM BioSciences, Inc.
YM BioSciences, Inc. Pharmaceuticals: MajorHealth Technology YM BioSciences, Inc. operates as a drug development company, which manufactures advancing hematology and cancer-related products. It is currently advancing in late-stage products, which include CYT387, an oral small molecule inhibitor of the kinase enzymes JAK1 and JAK2; and Nimotuzumab, an EGFR targeting humanized monoclonal antibody. The company was founded in 1994 and is headquartered in Mississauga, Canada. | 7 years |
| Emma McCann | F | - | 8 years | |
| Denis G. Bosc | M | - |
YM BioSciences, Inc.
YM BioSciences, Inc. Pharmaceuticals: MajorHealth Technology YM BioSciences, Inc. operates as a drug development company, which manufactures advancing hematology and cancer-related products. It is currently advancing in late-stage products, which include CYT387, an oral small molecule inhibitor of the kinase enzymes JAK1 and JAK2; and Nimotuzumab, an EGFR targeting humanized monoclonal antibody. The company was founded in 1994 and is headquartered in Mississauga, Canada.
Viventia Biotech, Inc.
Viventia Biotech, Inc. BiotechnologyHealth Technology Viventia Biotech, Inc. discovers, develops, manufactures, and commercializes monoclonal antibody products. Its products are used to treat head, neck, and bladder cancers. The company was founded by Albert D. Friesen in 1995 and is headquartered in Toronto, Canada | 4 years |
| Daniel J. Estes | M | 43 | 2 years | |
| Kapil Dhingra | M | 64 |
YM BioSciences, Inc.
YM BioSciences, Inc. Pharmaceuticals: MajorHealth Technology YM BioSciences, Inc. operates as a drug development company, which manufactures advancing hematology and cancer-related products. It is currently advancing in late-stage products, which include CYT387, an oral small molecule inhibitor of the kinase enzymes JAK1 and JAK2; and Nimotuzumab, an EGFR targeting humanized monoclonal antibody. The company was founded in 1994 and is headquartered in Mississauga, Canada. | 1 years |
| Jeffrey Cooper | M | 68 | 6 years | |
| Tryon Williams | M | 84 |
YM BioSciences, Inc.
YM BioSciences, Inc. Pharmaceuticals: MajorHealth Technology YM BioSciences, Inc. operates as a drug development company, which manufactures advancing hematology and cancer-related products. It is currently advancing in late-stage products, which include CYT387, an oral small molecule inhibitor of the kinase enzymes JAK1 and JAK2; and Nimotuzumab, an EGFR targeting humanized monoclonal antibody. The company was founded in 1994 and is headquartered in Mississauga, Canada. | 17 years |
| Philip Frost | M | 84 |
YM BioSciences, Inc.
YM BioSciences, Inc. Pharmaceuticals: MajorHealth Technology YM BioSciences, Inc. operates as a drug development company, which manufactures advancing hematology and cancer-related products. It is currently advancing in late-stage products, which include CYT387, an oral small molecule inhibitor of the kinase enzymes JAK1 and JAK2; and Nimotuzumab, an EGFR targeting humanized monoclonal antibody. The company was founded in 1994 and is headquartered in Mississauga, Canada. | 5 years |
| Wendi V. Rodrigueza | M | 58 | 10 years | |
| Barbara Klencke | M | 66 | 7 years | |
| Andrew Sinclair | M | 52 | 3 years | |
| Tran Nguyen | M | 50 | 3 years | |
| Pete de Spain | M | - | 7 years | |
| Alvin Vitangcol | M | 49 | 3 years | |
| Ofir Moreno | M | - | 12 years | |
| Catherine Mackey | M | 68 |
YM BioSciences, Inc.
YM BioSciences, Inc. Pharmaceuticals: MajorHealth Technology YM BioSciences, Inc. operates as a drug development company, which manufactures advancing hematology and cancer-related products. It is currently advancing in late-stage products, which include CYT387, an oral small molecule inhibitor of the kinase enzymes JAK1 and JAK2; and Nimotuzumab, an EGFR targeting humanized monoclonal antibody. The company was founded in 1994 and is headquartered in Mississauga, Canada. | 2 years |
| Albert Cha | M | 51 | 2 years | |
| Kevan E. Clemens | M | 80 | 7 years | |
| Sujay Kango | M | 60 | 2 years | |
| Andrew Allen | M | 57 | 5 years | |
| Cheryl Cohen | F | 58 | 2 years | |
| Nicole Onetto | M | 71 | 4 years | |
| Tamar Howson | F | 75 | 4 years | |
| Donald Parfet | M | 71 | 4 years | |
| Leah Cann | F | 63 | 7 years | |
| James Topper | M | 62 | 3 years | |
| Peter Thompson | M | 64 | 1 years | |
| François Thomas | M | 66 |
YM BioSciences, Inc.
YM BioSciences, Inc. Pharmaceuticals: MajorHealth Technology YM BioSciences, Inc. operates as a drug development company, which manufactures advancing hematology and cancer-related products. It is currently advancing in late-stage products, which include CYT387, an oral small molecule inhibitor of the kinase enzymes JAK1 and JAK2; and Nimotuzumab, an EGFR targeting humanized monoclonal antibody. The company was founded in 1994 and is headquartered in Mississauga, Canada. | 5 years |
| Gaurav Aggarwal | M | 51 | 3 years | |
| Mona Ashiya | M | 55 | 3 years | |
| Igor Gorbatchevsky | M | - | 2 years | |
| Alejandro Ricart | M | - | 1 years | |
| Tina Beamon | F | - | 2 years | |
| Jamie A. Tereschuck | F | - | - | |
| Josh Richardson | M | 42 | 3 years | |
| Christian Hassig | M | 52 | - | |
| Todd Butler | M | - | 2 years | |
| Brian Powl | M | 50 | - | |
| Leonardo Viana Nicacio | M | - |
YM BioSciences, Inc.
YM BioSciences, Inc. Pharmaceuticals: MajorHealth Technology YM BioSciences, Inc. operates as a drug development company, which manufactures advancing hematology and cancer-related products. It is currently advancing in late-stage products, which include CYT387, an oral small molecule inhibitor of the kinase enzymes JAK1 and JAK2; and Nimotuzumab, an EGFR targeting humanized monoclonal antibody. The company was founded in 1994 and is headquartered in Mississauga, Canada. | 2 years |
| Wendy J. Levin | M | - | - | |
| Sukhi Jagpal | M | 50 | 7 years | |
| Robert D. Mass | M | 70 | 11 years | |
| Ernest Shingyan Wong | M | 56 |
YM BioSciences, Inc.
YM BioSciences, Inc. Pharmaceuticals: MajorHealth Technology YM BioSciences, Inc. operates as a drug development company, which manufactures advancing hematology and cancer-related products. It is currently advancing in late-stage products, which include CYT387, an oral small molecule inhibitor of the kinase enzymes JAK1 and JAK2; and Nimotuzumab, an EGFR targeting humanized monoclonal antibody. The company was founded in 1994 and is headquartered in Mississauga, Canada. | - |
| Wendy Chapman | F | 58 |
YM BioSciences, Inc.
YM BioSciences, Inc. Pharmaceuticals: MajorHealth Technology YM BioSciences, Inc. operates as a drug development company, which manufactures advancing hematology and cancer-related products. It is currently advancing in late-stage products, which include CYT387, an oral small molecule inhibitor of the kinase enzymes JAK1 and JAK2; and Nimotuzumab, an EGFR targeting humanized monoclonal antibody. The company was founded in 1994 and is headquartered in Mississauga, Canada. | - |
| Karen Potts | M | 61 | - | |
| Keith E. Anderson | M | 55 | 7 years | |
| Chandra D. Lovejoy | F | 52 | 3 years | |
| Sean Thompson | M | - |
YM BioSciences, Inc.
YM BioSciences, Inc. Pharmaceuticals: MajorHealth Technology YM BioSciences, Inc. operates as a drug development company, which manufactures advancing hematology and cancer-related products. It is currently advancing in late-stage products, which include CYT387, an oral small molecule inhibitor of the kinase enzymes JAK1 and JAK2; and Nimotuzumab, an EGFR targeting humanized monoclonal antibody. The company was founded in 1994 and is headquartered in Mississauga, Canada. | - |
| Angie You | M | 51 | 4 years | |
| Richard A. Messmann | M | 67 | 4 years | |
| Benjamin Cadieux | M | - | 1 years |
Statistics
| Country | Connections | % of total |
|---|---|---|
| United States | 63 | 78.75% |
| United Kingdom | 13 | 16.25% |
| Canada | 8 | 10.00% |
Age of Connections
Active
Past
Male
Female
Members of the board
Executives
Origin of connections
- Stock Market
- Insiders
- Nick Glover
- Personal Network
